Blade Therapeutics
Manufacturing · 11-50 Employees
View Company Info for Free
Overview
Phone Number
(650) 278-4291Website
www.blademed.comRevenue
$20 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Blade Therapeutics
Blade Therapeutics is a private, clinical-stage biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. Blade's lead compound, BLD-2660, is a highly selective calpain inhibitor targeted for the treatment of chronic fibrotic diseases. BLD-2660 recently completed a Phase I, healthy volunteer, dose escalation study in Australia. The Company plans to initiate a Phase II trial in patients with idiopathic pulmonary fibrosis in early 2020. Blade's second candidate, BLD-0409, is a Phase I ready autotaxin inhibitor for the treatment of multiple fibrotic diseases. The Company plans to initiate a Phase 1 study for BLD-0409 in 1Q 2020. Blade has assembled a critical mass of anti-fibrotic drug development expertise within its top-tier leadership team and a world-class network of advisors. Lead investors in Blade include MPM Capital, Deerfield, Pfizer Ventures, One Ventures, Osage Partners, Bristol-Myers Squibb and Novartis Institute of Biomedical Research.Explore more
Blade Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Blade Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Blade Therapeutics
Blade Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Blade Therapeutics launches new products
Click to see if Blade Therapeutics had a recent Job posting/layoffs
Check out if Blade Therapeutics is spiking on competitors!
Check if Blade Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Blade Therapeutics has new funding data
Earning: See what the market has to say on Blade Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Blade Therapeutics
Find 3 more new buyers
Compare Similar Companies to Blade Therapeutics
Compare insights from companies similar to Blade Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Blade Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Blade Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Blade Therapeutics.
Blade Therapeutics financials insights
Gather financial insights about Blade Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$6.5M
2016
Series B
$45M
Blade Therapeutics Tech Stack
A closer look at the technologies used by Blade Therapeutics
Most Recent Scoops
Mergers & Acquisitions (M&A)
Facilities Relocation / Expansion
Blade Therapeutics is planning to move its offices in July 2022. The move will impact approximately 15 employees at their existing office located at 442 Littlefield Ave, South San Francisco, CA.
Mergers & Acquisitions (M&A)
Mergers & Acquisitions (M&A)
Blade Therapeutics News & Media
Blade Therapeutics Presents Analyses from Phase 1 and Preclinical Studies of Cudetaxestat at the European Respiratory Society International Congress 2022
SAN FRANCISCO--(BUSINESS WIRE)-- #ERS2022--Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced the presentation of positive data from Phase 1 and preclinical studies of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases. The data were featured in a poster (abstract #PA459) presented today at theBiotech Acquisition Company and Blade Therapeutics merger collapses - Labiotech.eu
A proposed merger between Biotech Acquisition Company (BAC) and Blade Therapeutics, Inc. has been terminated with immediate effect.Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination
Extraordinary General Meeting of BAC's shareholders postponed until a to-be-determined later date NEW YORK and SOUTH SAN FRANCISCO, Calif., June 2, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated...Biotech Acquisition Company Announces Submission of Prospectus Supplement to the Proxy Statement/Prospectus to The Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.
NEW YORK, May 24, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a submission to the United States Securities and Exchange Commission...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Blade Therapeutics
Sign Up For FreeTo access detailed company insights
Blade Therapeutics is a private, clinical-stage biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. Blade's lead compound, BLD-2660, is a highly selective calpain inhibitor targeted for the treatment of chronic fibrotic diseases. BLD-2660 recently completed a Phase I, healthy volunteer, dose escalation... Read More
